Anaemia in patients with myelomatosis

Wu, Ting; Cavill, I.; Jacobs, Alice K.; Kaaba, S.A.; May, Annette M.; Smith, Stuart A.; Whittaker, James A.

doi:10.1038/bjc.1982.141

Cited by 14 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the contrary, only in patients with renal failure has a defect in production and activity of EPO been suggested as the cause of anemia in MM [4,9]. In effect, renal failure is characterized by a real insufficiency in EPO production [9,10], such as confirmed by the reduced mesor in our patients. Moreover, renal failure, and not MM, seems to be responsible for the loss in EPO circadian rhythm.…”

Section: Discussionmentioning

confidence: 64%

“…The diurnal rhythm of EPO is preserved in patients with MM without renal impairment, suggesting, together with the observation of a higher mesor, that EPO does not seem to have a fundamental role in the pathogenesis of anemia in MM without renal impairment [4]. On the contrary, only in patients with renal failure has a defect in production and activity of EPO been suggested as the cause of anemia in MM [4,9]. In effect, renal failure is characterized by a real insufficiency in EPO production [9,10], such as confirmed by the reduced mesor in our patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circadian rhythm of serum erythropoietin in multiple myeloma

Pasqualetti

Collacciani²,

Casale

1996

Am. J. Hematol.

View full text Add to dashboard Cite

The diurnal rhythm in the circulating serum levels of erythropoietin (EPO) were determined in a group of 20 adult clinically-healthy subjects, in a group of 10 patients with myeloma without renal impairment and 10 patients with myeloma and renal failure. Venous blood samples were drawn during the span of a whole day and every 4 hr, starting from midnight, for the measurement of serum EPO levels by radioimmunoassay (RIA). Statistical analysis was carried out by means of the "cosinor" method. Results show that the controls and the myeloma patients without renal insufficiency present significant (P < 0.05) circadian rhythms in serum EPO levels; no rhythm (P < 0.05) was detected in patients with myeloma and renal failure. Patients with myeloma and renal failure have significant (P < 0.05) lower mean daily levels and diurnal fluctuations of EPO than the other groups, whereas the patients with myeloma without renal involvement present higher (P < 0.05) mean daily levels and lower (P < 0.05) diurnal variations of EPO than controls; no differences (P > 0.05) exist between the groups regarding peaks of rhythms. These data confirm the existence of a physiological circadian rhythm in serum EPO concentrations, with maximum in the afternoon, and they suggest that renal failure is an important cause of anemia and loss of EPO circadian rhythm in patients with myeloma.

show abstract

Section: Discussionmentioning

confidence: 64%

Section: Discussionmentioning

confidence: 99%

Circadian rhythm of serum erythropoietin in multiple myeloma

Pasqualetti

Collacciani²,

Casale

1996

Am. J. Hematol.

View full text Add to dashboard Cite

show abstract

“…Anemia associated with myeloma has been reported to arise from disordered maturation of the erythroblastic series, shortening of the lifespan of erythrocytes, and iron deficiency associated with an increased tumor cell mass, while hemolytic anemia has rarely been reported (1)(2)(3). Here, we report a case of multiple myeloma complicated by severe autoimmune hemolytic anemia at presentation, and discuss the relationship between the M-protein and the onset of such anemia.…”

Section: Introductionmentioning

confidence: 89%

Multiple Myeloma Complicated by Autoimmune Hemolytic Anemia

et al. 2004

View full text Add to dashboard Cite

“…In contrast, the ESR proved reliable in predicting prognosis, and bone marrow failure was usually observed in the progressive type. However, peripheral cytopenia may not be due entirely to replacement, as haematopoiesis may be depressed due to factors produced by the neoplastic cells (39), and, to the imbalance in T lymphocytes (implicated in haematopoiesis) recently observed in monoclonal gammopathies (40). These aspects must be considered when the effects of cytotoxic therapy on the bone marrow are assessed (41).…”

Section: Prognostic Factors and Survival In W Mmentioning

confidence: 99%

Bone Marrow Histology in Waldenström's Macroglobulinaemia

Bartl¹,

Frisch

Mahl

et al. 1983

Scandinavian Journal of Haematology

View full text Add to dashboard Cite

Bone marrow biopsies of 137 patients with Waldenström's macroglobulinaemia (WM), 26 with non‐secretory immunocytoma and 32 with benign monoclonal gammopathy were processed for histologic evaluation. Bone marrow involvement was found in 110 (80%) initially, and in 24 (18%) in sequential biopsies. 3 types were distinguished: lymphoplasmacytoid (47%), lymphoplasmacytic (42%) and polymorphous (11%) with median survivals of 74, 25 and 12 months, respectively. When grouped according to the tumour cell mass in the biopsies, the median survivals were 55, 21 and 8 months for < 20 vol%, 20–50 vol% and > 50 vol% respectively; in each subtype, the tumour cell mass correlated with the disease progression. 6 clinical variables were also found prognostically significant. These results demonstrate that (i) 98% of patients with WM have bone marrow involvement; (ii) the lymph node sub‐classification is applicable to the bone marrow and has both clinical and prognostic significance; (iii) patients may be staged according to the tumour cell burden in the bone marrow biopsy.

show abstract

Anaemia in patients with myelomatosis

Cited by 14 publications

References 23 publications

Circadian rhythm of serum erythropoietin in multiple myeloma

Circadian rhythm of serum erythropoietin in multiple myeloma

Multiple Myeloma Complicated by Autoimmune Hemolytic Anemia

Bone Marrow Histology in Waldenström's Macroglobulinaemia

Contact Info

Product

Resources

About